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A B S T R A C T
Herbal medicines and their bioactive compounds are increasingly being recognized as useful drugs for cancer
treatments. The parasitic fungus Cordyceps militaris is an attractive anticancer herbal since it shows very
powerful anticancer activity due to its phytocompound cordycepin. We previously discovered and reported that
a high amount of xylitol is present in Cordyceps militaris extract, and that xylitol unexpectedly showed antic-
ancer activity in a cancer-selective manner. We thus hypothesized that xylitol could become a useful supplement
to help prevent various cancers, if we can clarify the specific machinery by which xylitol induces cancer cell
death. It is also unclear whether xylitol acts on cancer suppression in vivo as well as in vitro. Here we show for the
first time that induction of the glutathione-degrading enzyme CHAC1 is the main cause of xylitol-induced
apoptotic cell death in cancer cells. The induction of CHAC1 is required for the endoplasmic reticulum (ER)
stress that is triggered by xylitol in cancer cells, and is linked to a second induction of oxidative stress in the
treated cells, and eventually leads to apoptotic cell death. Our in vivo approach also demonstrated that an
intravenous injection of xylitol had a tumor-suppressing effect in mice, to which the xylitol-triggered ER stress
also greatly contributed. We also observed that xylitol efficiently sensitized cancer cells to chemotherapeutic
drugs. Based on our findings, a chemotherapeutic strategy combined with xylitol might improve the outcomes of
patients facing cancer.
1. Introduction
Cancers remain a life-threatening disease. The consumption of foods
or supplements that supply safe anticancer ingredients on a daily basis
may help prevent the development of cancers by contributing to the
body's cancer resistance. Some compounds may also be useful even
when cancer emerges. We have been searching for new and effective
anticancer components among traditional Asian medicines, and we
have been focusing on the parasitic fungus Cordyceps militaris, a re-
nowned anticancer herbal medicine [1,2]. Cordyceps militaris exhibits
a very strong anticancer property [3] that is exerted by a well-known
compound, cordycepin [4, 5], and possibly also several unknown
components functioning in a cooperative manner.
We previously identified the anticancer monosaccharide xylitol in
an extract of Cordyceps militaris [2], and we observed that xylitol-
mediated apoptosis occurred in a cancer-selective manner [2]. We
therefore hypothesized that xylitol could be an effective and useful
daily food component for preventing cancer and lessening cancer ag-
gressiveness, as xylitol is not expensive (unlike cordycepin); xylitol is
also readily available and is already used in food products worldwide,
indicating a high level of safety.
However, it remains to be explained how xylitol triggers cancer-
specific apoptosis at the molecular level. It is also not clear whether
xylitol acts in an in vivo context for its anticancer ability; our previous
work is limited to in vitro approaches. We conducted the present study
to investigate potential mechanism(s) of xylitol-mediated cancer death
and the usefulness of xylitol in vivo.
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2. Materials and methods
2.1. Cell lines and chemicals
HEK293T cells (embryonic kidney cells stably expressing the SV40
large T antigen), MeWo cells (a human melanoma cell line), and PANC-
1 cells (a human pancreatic cancer cell line) were obtained from the
American Type Culture Collection (Manassas, VA). Normal human
OUMS-24 fibroblasts were established by Dr. Masayoshi Namba [6].
These human cells were all cultivated in D/F medium (Thermo Fisher
Scientific, Waltham, MA) supplemented with 10% fetal bovine serum
(FBS) in a humidified incubator filled with 5% CO2 at 37 °C.
The chemicals used in this study were as follows: xylitol (Wako,
Hiroshima, Japan), tauroursodeoxycholate (TUDCA) (Sigma-Aldrich,
St. Louis, MO), 5-fluorouracil (5-FU) (Sigma-Aldrich), dacarbazine
(Tokyo Chemical Industry, Tokyo), and N-Acetyl-L-cysteine (NAC)
(Tokyo Chemical Industry).
2.2. RNA-seq analysis
To identify gene(s) that play a role in xylitol-mediated apoptotic cell
death in cancer cells, we performed an RNA-seq-based comprehensive
analysis of gene expressions in MeWo cells that were treated or not
treated with xylitol, and we compared the altered gene expressions
among them. Total RNA was extracted from cells with ISOGEN (Nippon
Gene, Tokyo) according to the manufacturer's instructions. The isolated
RNA was subjected to an RNA-seq-based comprehensive analysis of
gene expression (Bioengineering Lab, Kanagawa, Japan).
2.3. Quantitative real-time PCR analysis
To confirm the results of the RNAseq analysis of selected genes, we
further investigated the genes' expression alterations caused by xylitol
in MeWo cells by conducting a quantitative real-time PCR analysis.
Total RNAs were extracted from the three cell lines with Isogen II
(Wako). The prepared RNAs (500 ng) from cultured cells were changed
to cDNAs by reverse-transcription with SuperScript™ II (Thermo Fisher
Scientific). A real-time reverse transcription-polymerase chain reaction
(RT-PCR) was performed by a LightCycler rapid thermal cycler system
(ABI 7900HT; Applied Biosystems, Foster City, CA) using a LightCycler
480 SYBR Green I Master (Roche Diagnostics, Indianapolis, IN). The
levels of mRNA expression were normalized relative to TBPmRNA as an
internal control, using the ΔΔCt method.
The following forward and reverse primer pairs (5′ to 3′) were used:
CHAC1 (forward: AGGGAGACACCTTCCATCG; reverse: CTCCCCTTGCA
CTTGGTATG), HIPK2 (forward: CAGCACCAGTCATCTGTGAGA; reverse:
TCTCCTTGACACGCTTGGAT), MAFK (forward: CCAAACCGAATAAGGC
ATTAAA; reverse: CCTCCTCCTTGGTGAGACC), RERE (forward: CACCT
CCACCAGCAGGAC; reverse: GAGGGTTGGGGAGAGTGC), BCAP29 (for-
ward: TTTTTGGAACAAGGCTTTCC; reverse: GGTGGAGCTCTTCTCAA
TGG), MRPL34 (forward: TCAAACGCAAGAACAAGCAC; reverse: AATG
GCTCAGCGACTTGC), PIR (forward: ACAGCAGTGCTTGGAGAAGG; re-
verse: GCTCCCCAGCAATTAAGACA), RPP21 (forward: CTCTCTGTCGA




To examine the possible role(s) of CHAC1 in cancer cells, we per-
formed RNA interference experiments. Human CHAC1 siRNA (siCHAC1
#0, sense: CCCAUACUGUUACCCAUAAtt and antisense: UUAUGGGUA
ACAGUAUGGGac; siCHAC1 #1, sense: CUACUUGAAACUUUAUUUAtt
and antisense: UAAAUAAAGUUUCAAGUAGta; siCHAC1 #2, sense:
GGCUGGAUGAGGGAUAGUAtt and antisense: UACUAUCCCUCAUCCA
GCCtg) and control siRNA (control glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) siRNA, sense: UGGUUUACAUGUUCCAAUAtt and
antisense: UAUUGGAACAUGUAAACCAtg) were purchased from Thermo
Fisher Scientific. Each siRNA was transfected to the cells using
Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific) at a final
concentration of 10 nM in culture. After 24-h exposure to the transfection
mixture, the gene-silencing efficiency of the cells was measured by a
quantitative real-time PCR analysis.
2.5. Western blotting
To determine the protein expression levels of interest in the cells
and tissues, we carried out a Western blot analysis. The collected cell
pellets were lysed by pipetting in ice-cold M-PER buffer (Thermo Fisher
Scientific) and kept on ice for 30 min. The tumor tissues dissected from
mice were thoroughly homogenized by a homogenizer (UD-201; Tomy
Seiko, Tokyo) and kept on ice for another 30 min. After centrifugation
of the suspensions at 15,000 rpm for 20 min, the clear supernatants
were prepared as whole protein lysates.
The protein concentrations of all the prepared whole lysates were
measured according to the Bradford method using a Bio-Rad protein
assay kit (Bio-Rad Laboratories, Hercules, CA). A total of 10 μg of
protein lysate was loaded onto a 12% sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) gel, separated according to
the molecular weights, and transferred to polyvinylidene difluoride
(PVDF) membranes. The membranes were blocked with 10% skim-
milk/PBST for 1 h at room temperature, and then incubated with the
following primary antibodies at 4 °C overnight: rabbit anti-human
CHAC1 (Proteintech, Tokyo), rabbit anti-human binding im-
munoglobulin protein (BiP) (Cell Signaling Technology, Danvers, MA),
rabbit anti-human cleaved caspase-3 (Asp175) (Cell Signaling
Technology) or mouse anti-human α-tubulin (Sigma-Aldrich) followed
by incubation with secondary antibodies (horseradish peroxidase
[HRP]-conjugated anti-mouse or anti-rabbit IgG antibody [Cell
Signaling Technology]) at room temperature for 1 h.
Abbreviations
ATF4 activating transcription factor 4
ATF6 activating transcription factor 6
ATP adenosine-3′-triphosphate
BiP binding-immunoglobulin protein
CBB coomassie brilliant blue
CD44v CD44 variant isoform
CHAC1 ChaC glutathione specific gamma-glutamylcyclotrans-
ferase 1






IRE1α inositol-requiring protein 1 alpha
NAC N-Acetyl-L-cysteine
PAGE polyacrylamide gel electrophoresis
PERK PKR-like ER kinase
PVDF polyvinylidene difluoride
ROS reactive oxygen species
RT-PCR reverse transcription-polymerase chain reaction
SDS sodium dodecyl sulfate
TUDCA tauroursodeoxycholate
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Target protein bands were visualized on x-ray film that covered the
reacted PVDF membrane with a chemiluminescence system (Pierce ECL
Plus, Thermo Fisher Scientific). Considering the nature of the experi-
mental settings and the specimens used, either detection of tubulin with
western blotting or total protein staining of the SDS-PAGE gels with
Coomassie brilliant blue (CBB) was used as a loading control.
2.6. Electrophoretic mobility shift assay (EMSA)
We performed an electrophoretic mobility shift assay (EMSA) to
investigate the possible mechanism and the role of the selected tran-
scription factors, i.e., ATF4 and NFκB. Nuclear extracts from MeWo
cells were prepared in accord with the manufacturer's instructions,
using NE-PER Nuclear Extraction Reagent (Thermo Fisher Scientific).
The protein concentrations of the prepared nuclear extracts were
measured according to the Bradford method as described above in the
Western blotting section. The 5′-biotin-labeled double-stranded probes
(ATF4: forward: 5′-aaGGATGATGCAATAcc-3′ and reverse: 3′-ggTATT
GCATCATCCtt-5'; NFκB: forward: 5′-agttgaGGGGACTTTCCcaggc-3′ and
reverse: 3′-gcctgGGAAAGTCCCCtcaact-5′) were purchased from Sigma-
Aldrich.
The DNA probes were mixed with 2 μg of crude nuclear extracts in a
reaction mixture (20 μl) containing 60 mM KCl, 5 mM MgCl2, 0.1 mM
EDTA, 1 μg of poly (dI-dC), 1 mM dithiothreitol, 5% glycerol, and
20 mM HEPES (pH 7.9) and incubated on ice for 30 min. DNA-protein
complexes were then separated by electrophoresis in a 7% poly-
acrylamide gel (PAGE) under non-denaturing conditions and blotted
onto a Biodyne B nylon membrane (Pall, Tokyo). The bands were de-
tected using a LightShift Chemiluminescent EMSA kit (Thermo Fisher
Scientific) according to the manufacturer's instructions.
2.7. Evaluation of cellular apoptosis, ROS, glutathione, and ATP
To evaluate apoptotic cell death and its related oxidative stress, we
conducted the following assays. Apoptotic cells were detected as de-
scribed previously [1, 2]. Briefly, a cell culture stained with
Hoechst33342 solution (Thermo Fisher Scientific) at a final con-
centration of 5 μg/ml was incubated for 30 min. We then used fluor-
escence microscopy to observe apoptotic cells that showed markedly
high brightness with Hoechst staining due to the apoptosis-induced
shrinking of their nuclei, which could be readily distinguished from the
nuclei of non-apoptotic cells. Each well was microscopically imaged in
five distinct regions at 200 × magnification in triplicate. The numbers
of apoptotic cells (showing bright blue fluorescence) and total cells
(apoptotic cells and non-apoptotic cells showing dark blue fluores-
cence) to the five non-overlapping regions were counted and then
summed as the total apoptotic cell number and the total cell number,
respectively. The numbers of apoptotic cells are presented as the
averages of the percentages of all cells from three independent ex-
periments. Cellular apoptosis was evaluated by the detection of cleaved
caspase-3 by western blotting (see the Western blotting section). The
intracellular levels of reactive oxygen species (ROS), glutathione (re-
duced type: GSH), and adenosine-3′-triphosphate (ATP) were measured
by using the following respective kits: the ROS Detection Cell-Based
Assay Kit (DHE) (Cayman Chemical, Ann Arbor, MI), the Amplite™
Fluorimetric Glutathione Assay Kit Green Fluorescence (AAT Bioquest,
Sunnyvale, CA), and the ATP Detection Assay Kit-Luminescence
(Cayman Chemical).
2.8. Animal experiments
To expand the in vitro study of xylitol to an in vivo investigation, we
carried out an evaluation of the anticancer effect(s) of xylitol on a
cancer-bearing mouse model. The experimental protocols were ap-
proved by the Animal Experiment Committee at Okayama University
(approval no. OKU-2017250). All mouse procedures and euthanasia,
including cell transplantations, were done painlessly or with the mouse
under anesthesia, within the Committee's strict guidelines.
For the evaluation of tumor growth in vivo, MeWo cells
(2 × 106 cells) mixed with Matrigel were subcutaneously transplanted
into the back on the right side of BALB/c-nu/nu mice (CLEA Japan,
Tokyo). The size of each tumor was measured with Vernier calipers, and
the tumor volume was calculated as 1/2 × (shortest dia.)2 × (longest
dia.). For a series of xenograft experiments, all mice were randomly
divided into two groups (Fig. 4) or four groups (Fig. 5, 6A–D), at five
mice per group.
2.9. Treatment procedure
We selected the doses of the chemicals used in this study by referring
to the IC50 and LD50 values of these chemicals reported in scientific
journals and the publicly available data provided by medical companies.
For xylitol, these values were IC50 = 6.77% in A549 cells and 5.88% in
HCT-115 cells [7], and LD50 > 4000mg/kg per mouse (a single injection
via the tail vein) [8]). For TUDCA, they were LD50 > 600–800 mg/kg
per rat (a single injection via the tail vein) (https://patentimages.storage.
googleapis.com/f9/17/63/c83e303b27c9d4/EP0773029A1.pdf). For 5-
FU, they were IC50= 50 μg/ml in MeWo cells [9], and LD50 > 250 mg/
kg per mouse (a single injection via the tail vein) (website: https://
medical.kyowakirin.co.jp/site/drugpdf/interv/5fu_iv_in.pdf). For da-
carbazine, they were IC50 = 500 μg/ml in MeWo cells [9], and
LD50>around 470 mg/kg per mouse (a single injection via the tail vein
[10]). We set the chemical doses and their treatment-time schedules based
on the above information.
In the in vitro culture system, cells were treated with xylitol in the
range of 1 mg/ml (0.1%) to 50 mg/ml (5%) (final concentration) for
either 24 or 48 h according to the experimental settings. Cells were also
treated with dacarbazine (0 μM, 100 μM [18 μg/ml], or 500 μM
[100 μg/ml]) with or without xylitol (25 mg/ml, 2.5%) for 48 h. The
percentage of apoptotic cells in the control culture of the intact cells
generally reaches approximately 10%. To more clearly show the effect
of xylitol on the number of apoptotic cells, we added xylitol to the
cultures just after the replacement with fresh medium to allow the re-
moval of the apoptotic cells that were already present in the control
cultures.
For the in vivo animal experiments, we used 2.0 g/kg of xylitol. The
reason for this dose is as follows. The in vitro effective and maximum
dose is 25 mg/ml. Given that the weight of one mouse is ~20 g, its total
blood will be ~2 ml in volume so that the following is obtained: 25 mg/
ml = 50 mg/2 ml (blood volume) = 50 mg/20 g (mouse weight). This
ratio is comparable to 2.5 g/kg. Considering that differences between in
vitro and in vivo environments may lead to unexpected side effects in a
living body, we finally defined 2.0 g/kg as an applicable dose to each
mouse after contemplating a slight reduction from the calculated dose
(2.5 g/kg). The concentration 2.0 g/kg is one-half of the LD50 (4 g/kg)
of xylitol per mouse as mentioned above.
For the treatment schedule, in consideration of a previous report
describing the half-life of xylitol in rats as approx. 7–8 h [11], we
decided to administer xylitol to the mice at the same dose ratio (2.0 g/
kg) on a daily basis.
After a tumor had grown at the injected site to 50–100 mm3 in
volume, either control phosphate-buffered saline (PBS) or xylitol
(2.0 g/kg in PBS) was orally or intravenously administered daily to the
mice. The ER-stress inhibitor sodium tauroursodeoxycholate (TUDCA;
250 mg/kg in PBS) [12, 13] was further injected intraperitoneally on
day 7 and subsequently injected every other day in the same way.
2.10. Statistical analysis
All values are expressed as the mean ± SD. All data were analyzed
by unpaired Student's t-test for significant differences between the
mean values of each group.
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3. Results
3.1. Xylitol induced apoptotic cell death in cancer cells via oxidative stress
We previously reported that the xylitol content in our prepared
Cordyceps militaris extract was 2.34 mg/ml [2]. In the present study,
therefore, we evaluated the dependence of the induction of the apop-
tosis of melanoma cells on the dose of xylitol, starting with 2 mg/ml as
the lowest concentration. As shown in Fig. 1A, we confirmed that 24-h
treatment with xylitol induced apoptotic cell death in MeWo cells in a
dose-dependent manner. The 50 mg/ml dose showed the greatest effect
in this context. In parallel with this experimental setting, the xylitol-
(caption on next page)
N. Tomonobu, et al. Chemico-Biological Interactions 324 (2020) 109085
4
mediated apoptosis in MeWo cells was also confirmed by another
method, i.e., the western blot-based detection of the cleaved caspase-3.
By this approach, we confirmed that the cleaved caspase-3 was present
in the cell extracts treated with 5 mg/ml of xylitol, and the detected
band was further increased in a dose-dependent manner
(Supplementary Fig. S1).
Although 50 mg/ml of glucose could not induce apoptosis in MeWo
cells (data not shown) due to the somewhat high osmotic pressure for
50 mg/ml (329 mOsm/L) compared to physiological pressure
(285 ± 5 mOsm/L), we decided to use 25 mg/ml as the highest xylitol
dose in a series of in vitro experiments. The xylitol-mediated apoptotic
cell death was further enhanced by treatment with xylitol for another
48 h, to a significant level (Fig. 1A). To obtain insights into the cellular
events relevant to this xylitol-induced apoptosis, we then examined the
cellular oxidative state, since it is closely associated with the cellular
apoptotic process in many physiological scenarios. As we expected, the
apoptosis induced by 25 mg/ml of xylitol was followed by a marked
elevation of ROS (Fig. 1B). In parallel with this, the reduced glutathione
(GSH) level was also significantly reduced, whereas the ATP showed
only a slight reduction. The xylitol-mediated reduction of the GSH level
was further confirmed by another method (Supplementary Fig. S2).
Interestingly, the xylitol-mediated apoptotic cell death was significantly
attenuated by the pretreatment with an ROS inhibitor, NAC
(Supplementary Fig. S3), suggesting that ROS are highly involved in the
xylitol-mediated apoptotic process of cancer cells.
In light of these cellular events, we next sought to identify key gene
(s) that may play a critical role in the xylitol-mediated cancer death.
The results of the RNA-seq analysis (Fig. 1C) revealed several genes of
interest. We focused on the genes marked in red in Fig. 1 because these
selected genes are highly associated with apoptotic events that occur
with the regulation of oxidative stress, and with mitochondria, DNA
replication, and protein translation. The genes are as follows. CHAC1:
Regulates glutathione levels and oxidative balance in cells. HIPK2: In-
hibits cell growth and promotes apoptosis through the activation of
p53. MAFK: Functions as a transcriptional regulator in response to
oxidative stress. RERE: Functions as a transcriptional regulator in re-
sponse to oxidative stress. BCAP29: Involved in CASP8-mediated
apoptosis. MRPL34: Functions as a mitochondrial ribosome. PIR: In-
volved in the regulation of DNA transcription and replication. RPP21:
Generates mature tRNA molecules by cleaving their 5-ends.
As we noted in the Introduction section, Cordyceps militaris exhibits
a very strong anticancer property [3] due to two of its constituent
compounds, xylitol [2] and the well-known cordycepin [4, 5]. To con-
firm the specific induction of these genes by xylitol, we next conducted
a quantitative-real time PCR for the selected genes. The confirmation
approach showed that the CHAC1 gene was induced at a much higher
level compared to both the not-treated and cordycepin-treated cases
(Fig. 1D). We thus decided to focus on CHAC1 as an important gene that
may regulate apoptosis in response to xylitol but not cordycepin.
3.2. CHAC1 plays a part in the xylitol-mediated cancer cell death
To test whether the xylitol-mediated apoptosis is limited to malig-
nant MeWo cells (and does not affect normal cells), we investigated the
effects of xylitol on another type of human cancer cells and on normal
human fibroblasts. As shown in Fig. 2A, we observed that the human
pancreatic cancer PANC-1 cells showed an apoptotic phenotype like
that of the MeWo cells after xylitol treatment, whereas OUMS-24 fi-
broblasts did not show any appreciable apoptotic phenotype. As shown
in Fig. 2A, this selective apoptotic event in cancer cells was further
confirmed by our similar independent experiments that included other
pancreatic cancer cell lines, AsPC-1 and MIA PaCa-2 (Supplementary
Fig. S4A). In addition, ROS were constantly induced at a significant
level in the cancer cell lines, but the induction did not occur in the
normal OUMS-24 cells (Supplementary Fig. S4B), and there was also no
induction of apoptosis cells in the normal OUMS-24 cells
(Supplementary Fig. S4A). Interestingly, the xylitol-mediated apoptotic
event also matched the induction rate of CHAC1 in all cell types ex-
amined, i.e., OUMS-24, MeWo and PANC-1 (Fig. 2B).
CHAC1 was next downregulated by an RNAi technique for the as-
sessment of its relevance to apoptotic cell death. We first checked the
effect of CHAC1 siRNAs (siCHA1 #0, #1 and #2; see the siRNA section
above) on the downregulation of the intrinsic CHAC1 expression in two
cell lines, MeWo and HEK293T. The results revealed that, among the
siRNAs used, siCHAC1 #1 caused the highest reduction of CHAC1
(Fig. 2C). Because it was the most effective, we then treated cells with
siCHAC1 #1 and found that the xylitol-induced apoptotic cell death was
dramatically attenuated (Fig. 2D). The siRNA also caused a down-
regulation of the xylitol-mediated ROS production and inversely re-
stored the glutathione level. The ATP level was not changed even after
siRNA treatment. Considering that CHAC1 is major glutathione-de-
grading enzyme [14], the xylitol-mediated increase in ROS is rational.
3.3. Xylitol induced ER stress
It has been reported that CHAC1 induction is transcriptionally
regulated by ATF4 via ER stress [14–16], and we therefore investigated
the potential ability of xylitol to induce ER stress. An induction of the
major ER chaperone, binding-immunoglobulin protein (BiP), is a reli-
able index marker for the observation of cellular events following ER
stress. In non-stressed cells, BiP binds and inhibits three representative
ER stress sensors: inositol-requiring protein 1 alpha (IRE1α), activating
transcription factor 6 (ATF6), and PKR-like ER kinase (PERK). Upon the
induction of ER stress, BiP is recruited by the misfolded proteins and is
subsequently released from the three sensors [17]. The resulting free
sensors all undergo autoactivation and induce their own signaling
cascades that are relevant to multiple cellular events of the ER stress. In
this experimental setting, we thus sought to determine whether cells
react to ER stress by evaluating the induction levels of BiP protein after
treating the cells with xylitol.
As shown in Fig. 3A, xylitol but not glucose significantly induced
BiP protein in parallel with CHAC1 induction in a dose-dependent
manner. In addition, when we used an ATF4-specific probe (Fig. 3B) to
search for the ATF4 activation state after xylitol treatment, the results
confirmed that ATF4 (Fig. 3C, left) but not NFκB (Fig. 3C, right) was
highly upregulated in response to xylitol, in a manner similar to the
induction of BiP and CHAC1 proteins (Fig. 3A).
3.4. Xylitol mitigated melanoma growth in vivo through ER stress
Since the results obtained thus far demonstrated that xylitol plays a
part in selective cancer death in vitro, we next investigated whether
Fig. 1. The induction of the apoptotic cell death of MeWo cells by xylitol and the identification of CHAC1 as one of the top-rated genes relevant to the xylitol-
mediated apoptosis. A: MeWo cells were treated with xylitol at 0–50 mg/ml for 24 h (left and middle). The detection of apoptotic cell death was achieved by Hoechst
33342 staining, which brings bright fluorescence to the cells displaying apoptotic nuclear shrinkage. Left panel: Cell-stained images at 24 h. Scale bars: 50 μm. Middle
panel: Quantified data from the counting of apoptotic cells at 24 h. Right panel: Quantified data from the counting of apoptotic cells at 48 h after treatment with xylitol
(25 mg/ml). B: MeWo cells were treated with xylitol at a final conc. of 25 mg/ml for 24 h. Hoechst-based counting of apoptotic cells and measurements of cellular
glutathione, ROS, and ATP were performed. C: Heat maps from the data of RNA-seq are displayed for the picked-up genes that were up- and downregulated in MeWo
cells after xylitol treatment. These analyses were performed using the database for annotation, visualization and integrated discovery (DAVID) v6.8 (http://david.
ncifcr.gov/). D: The mRNA expression of the selected genes relative to TBP as the internal control were evaluated in MeWo cells, which were not treated or were
treated with xylitol or cordycepin as determined by qRT-PCR. Data are mean ± SD. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001 by Student's t-test.
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Fig. 2. The critical role of CHAC1 in xylitol-mediated apoptotic death in cancer cells. A,B: Human melanoma MeWo cells, human pancreatic PANC-1 cells, and
normal human OUMS-24 fibroblasts were treated with xylitol at a final conc. of 25 mg/ml for 24 h. Apoptotic cells were detected by Hoechst staining and then
quantified (A) and CHAC1 induction was detected by Western blot (B). C: The prepared CHAC1 siRNAs (#0, #1, #2) were checked for their downregulating effects
on the intrinsic CHAC1. Top: MeWo cells. Bottom: HEK293T cells. D: MeWo cells were transfected with either siCHAC#1 or siGAPDH as a control for 24 h and then
treated with xylitol at a final conc. of 25 mg/ml for another 24 h. Hoechst-based counting of apoptotic cells (left-top panel) and measurements of cellular glutathione
(right-top), ROS (left-bottom) and ATP (right-bottom) were performed. Data are mean ± SD. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001 by Student's t-
test.
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xylitol also works in vivo. The administration route may be important
for the appropriate action of xylitol against cancer in vivo, and we thus
administered the same amount of xylitol by an oral route (Fig. 4A and
B) and via the tail vein of mice (Fig. 4C–F). In these in vivo models, we
used 2.0 g/kg because this dose is similar to the in vitro effective and
maximum dose (25 mg/ml). We considered this dose safe, since the
LD50 in mice is 10-fold higher than the selected dose at either an oral
[8] or intravenous [8] route.
Because the half-life of xylitol in rats is approx. 7–8 h [11], we
administered xylitol at the same dose to the mice on a daily basis. With
this approach, we observed that the oral administration had no effect
on the MeWo cell-derived tumor volume (Fig. 4A) or weight (Fig. 4B),
whereas the intravenous injection attenuated the tumor growth rate
(Fig. 4C). Throughout the monitoring period, the body weights of the
mice were not affected by the xylitol treatment (Fig. 4D). On day 15, we
observed again that the tumor weights were actually decreased in the
xylitol-treated group (Fig. 4E), and this was also true of the tumor
volumes (Fig. 4C).
Like glucose, xylitol can also be used in glycolysis [18], which plays
a fundamental role in cancer cell growth through the production of ATP
energy. In the present experiment, the glycolysis occurred particularly
in the tumor masses grown in an in vivo environment compared to the in
vitro monolayer culture system, since inside of a tumor mass displays a
high level of hypoxia. We therefore examined the glycolysis state of the
xylitol-treated tumors (the MeWo cell-derived tumors) in a comparison
with the control PBS-treated groups. The mass spectrometry-based
analysis of metabolites showed no appreciable alterations of the major
metabolites produced by glycolysis (Supplementary Fig. S5), suggesting
Fig. 3. The induction of CHAC1 by the xylitol-triggered ER-stress. A:MeWo cells were treated with glucose or xylitol at the indicated doses for 24 h. BiP and CHAC1
were detected by western blots using the prepared whole cell extracts. B: Consensus sequence of the ATF4 responsive cis-element (http://jaspar.genereg.net/matrix/
MA0833.1/). C: EMSA was performed after the preparation of cell specimens under conditions similar to those described for panel (A) except for the use of nuclear
extracts. Left panel: Detection of the ATF4 probe. Right: Detection of the NFκB probe.
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Fig. 4. The tumor-suppressive function of xylitol in
vivo. A,B: MeWo cell-derived tumor sizes were mon-
itored on the indicated days. Xylitol (2.0 g/kg in PBS,
which corresponds to approx. 20 mg/ml in vitro) was
orally administered starting at day 0 (the tumor vo-
lumes reached ~50–100 mm3) and then every day
until the monitoring was discontinued (A). On day 15,
the resected tumors were all weighed (B). C–F: MeWo
cell-derived tumor sizes (C) and body weights (D)
were monitored on the indicated days after the ad-
ministration of xylitol (2.0 g/kg in PBS) by way of the
tail vein starting at day 0 and then daily. Tumor
weights were quantified (E) and tumor images were
taken (F) 15 days after the administration. G: On day
15, the resected tumors were collected, lysed, and
subjected to SDS-PAGE, and then the protein levels of
BiP and CHAC1 were evaluated by western blots.
Bottom: CBB staining showing the internal control and
proper loading of the protein specimens. Data are
mean ± SD. ns, not significant; *p < 0.05,
**p < 0.01, ***p < 0.001 by Student's t-test.
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that xylitol might not affect the glycolysis process in tumors in vivo.
Notably, although in the PBS-treated mice the tissue surrounding
the tumor front had become very rough, representing a highly invasive
tumor phenotype, the tumor front in the xylitol-treated cases was very
smooth, suggesting that xylitol has an ability to suppress not only
cancer growth but also cancer invasiveness (Fig. 4F). In this setting, we
also examined the induction of ER stress and the subsequent CHAC1
status in vivo. We detected a significant accumulation of BiP as well as
CHAC1 in the xylitol-treated tumor groups in a common manner that
occurred specifically in the intravenous administration but not the oral
Fig. 5. The ER stress-dependent tumor-suppressive
function of xylitol in vivo. A–D: MeWo cell-derived
tumor sizes were monitored on the indicated days.
Xylitol (2.0 g/kg in PBS) was administered via the
tail vein starting at day 0 (the tumor volumes
reached approx. 50–100 mm3) and then daily (A).
Regarding panel (A), the ER-stress inhibitor TUDCA
(250 mg/kg in PBS) was further intraperitoneally
administered to PBS- or xylitol-treated mice starting
on day 7, and the mice underwent the same injection
every other day (A). In parallel with (A), body
weights were also monitored (B). Tumor weights
were quantified (C) and tumor images were taken
(D) 15 days after the administration. (E) On day 15,
the resected tumors were collected, lysed, and sub-
jected to SDS-PAGE, and then the protein levels of
BiP and CHAC1 were evaluated by western blots.
Bottom: CBB staining showing the internal control
and proper loading of the protein specimens. Data
are mean ± SD. ns, not significant; *p < 0.05,
**p < 0.01, ***p < 0.001 by Student's t-test.
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administration (Fig. 4G).
ER stress is also likely to play a crucial role in the xylitol-induced
tumor suppression in in vivo settings just as it does in in vitro settings.
We therefore used the major ER-stress inhibitor TUDCA in the same
experiment, as TUDCA may cancel the effect of xylitol. TUDCA was
used at 250 mg/kg since this concentration has been reported as an
effective dose that works sufficiently in a mouse model [12]. As ex-
pected, TUDCA effectively canceled the xylitol-mediated tumor
suppression (Fig. 5A). The body weights of the mice were not affected
by any of the treatments in the experiment (Fig. 5B). On day 15, the
tumor weights in the xylitol-treated groups had caught up to almost the
same levels as those of the PBS-treated tumor groups (Fig. 5C).
Our examination of the tumor images derived from each group re-
vealed a smooth interface representing non-aggressiveness only in the
xylitol-treated groups; this phenotype turned into an aggressive phe-
notype after xylitol was combined with TUDCA (Fig. 5D). The results
Fig. 6. The increased tumor-suppressive function of
5-FU by blending with xylitol. A: MeWo cells were
treated with 5-FU (50 μg/ml) in the presence or
absence of xylitol (25 mg/ml). After 24-h (left) or 48-
h (right) treatment of the cells, in vitro apoptotic as-
sessments were carried out. B–D: MeWo cell-derived
tumor sizes (B) and body weights (C) were mon-
itored on the indicated days after the administration
of xylitol (2.0 g/kg in PBS) combined with or
without 5-FU (50 μg/kg) or single 5-FU (50 μg/kg)
via the tail vein starting at day 0 and then daily for
xylitol and weekly for 5-FU. Tumor weights were
quantified (D) 14 days after the administration. E:
MeWo cells were treated with dacarbazine (0, 100,
or 500 μM) in the presence or absence of xylitol
(25 mg/ml). After 48-h treatment of the cells, in vitro
apoptotic assessments were carried out. Data are
mean ± SD. ns, not significant; *p < 0.05,
**p < 0.01, ***p < 0.001 by Student's t-test.
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also confirmed that TUDCA efficiently blocked both the BiP induction
and CHAC1 induction caused by xylitol (Fig. 5E). These results indicate
that xylitol has a tumor-suppressive function when intravenously ad-
ministered, and this function is dependent on the presence of some level
of ER stress.
3.5. Xylitol sensitized melanoma cells to chemotherapeutic drugs
The oxidative stress caused by the xylitol-mediated glutathione re-
duction may enhance the effect of chemotherapeutic drugs. In fact, our
previous study demonstrated that xylitol markedly reinforces the cor-
dycepin-mediated apoptosis of cancer cells [2]. We examined this fur-
ther herein. As expected, xylitol effectively sensitized melanoma cells to
a 5-FU anticancer chemical in vitro (Fig. 6A) as well as in vivo
(Fig. 6B–D). The in vitro sensitization effect of xylitol was also observed
for another compound, dacarbazine, which is clinically approved for
treating melanoma (Fig. 6E). Our results thus suggest that xylitol en-
hances the effects of chemotherapeutic drugs for cancer prevention.
4. Discussion
4.1. Molecules associated with the apoptotic machinery triggered by xylitol
in cancer cells
Our present findings demonstrated that xylitol has a prominent
cancer-suppressing ability in an in vitro cell culture system as well as in
an in vivo cancer-bearing mouse model. In the mouse model, the oral
administration of xylitol had no effect on the cancer suppression,
whereas the intravenous injection of xylitol prevented cancer growth,
probably due to some type of acid-mediated inactive modification or
degradation of xylitol; otherwise, there would be an insufficient ab-
sorbance of xylitol into the blood by way of the oral-gastric route. Our
mechanistic studies also showed that xylitol-mediated cancer apoptosis
was triggered by the upregulation of CHAC1 (which originates in ATF4
activation via xylitol-triggered ER stress), eventually leading to oxida-
tive stress since CHAC1 enzymatically degrades intracellular glu-
tathione [14–16].
We examined these events mainly in MeWo cells, and some key
findings were confirmed in other types of cancer cells (e.g., PANC-
1 cells, AsPC-1 and MIA PaCa-2 cells) (Supplementary Fig. S4), and thus
our proposed pathway is not restricted to only a single cell line. On the
other hand, the xylitol-mediated apoptotic pathway as described above
does not appear to be involved in normal human OUMS-24 fibroblasts,
suggesting that xylitol could be an effective and useful daily food
component for preventing cancers in a selective manner.
Here, our primary question was whether the xylitol-mediated
apoptotic cell death is explained by CHAC1 alone. As shown by the
results of the RNA-seq-based analysis (Fig. 1C), in addition to CHAC1,
other molecules that may be related to apoptosis and growth regula-
tion, such as HIPK2, MAFK, RERE, BCAP29, MRPL34, PIR and RPP21,
attracted our attention. However, the reproducibility of their inductions
by xylitol treatment was not shown by the confirmation study based on
the quantitative real-time PCR analysis results (Fig. 1D), and we thus
omitted these genes from the xylitol pathway. We speculate that there is
no close link between CHAC1 and the omitted individual genes. In
addition, we did not observe any association between ER stress and
these omitted genes (except for HIPK2) in our review of the relevant
published studies. Lee et al. reported that ER stress-mediated neuro-
degeneration in amyotrophic lateral sclerosis (ALS) is promoted by the
induced HIPK2 [19]. This may indicate that xylitol-mediated ER stress
is different in nature from the ER-stress caused by ALS disease.
Our second question concerned the results provided in Fig. 2D: why
did the decrease of CHAC1 expression induced by the siRNA cause a
moderate suppression of the xylitol-induced ROS production in MeWo
cells? This result may indicate that ER stress-mediated CHAC1 is not the
only source of ROS in the xylitol-treated cells. Similarly, CHAC1
induction may not be the only event responsible for the anticancer
properties of xylitol, as shown in the in vivo studies. Because quite a few
molecules would be regulated by xylitol-mediated ER stress, it is surely
possible that molecule(s) other than CHAC1 also contribute to the xy-
litol-mediated anticancer machinery. In this study, our experiments
searching for important molecules involved in the control of xylitol-
mediated cancer apoptosis were only conducted at the RNA level. Since
mRNA expressions do not always reflect the corresponding protein le-
vels, comprehensive analyses at the protein level could lead to the
identification of additional important regulators that will clarify the
CHAC1-integrated or not-integrated mechanism(s) of the anticancer
role of xylitol. This subject is part of our ongoing research.
4.2. Xylitol-mediated ER stress
In the context of the mechanism proposed above, it is not yet known
how ER stress is exerted by xylitol incorporation in cancer cells.
Intracellular metabolite(s) of xylitol may provide a clue. One of the
xylitol metabolites, xylulose-5-P, was reported to be able to inhibit the
glycolysis system in mammalian cells [20]. Thereby, the glycolysis-
produced ATP level may be significantly reduced by xylitol, since ATP
is required for protein folding. However, we observed that xylitol did
not consume ATP at a much higher level in the treated cells (Figs. 1B
and 2D), and in our additional studies, the xylitol-derived apoptotic cell
death was not affected by a hypoxic environment that shifts the mi-
tochondria-based ATP production to glycolysis-based ATP production
(data not shown).
In light of those findings and reports, we speculated that xylitol
might disturb the normal protein glycosylation in the ER. Because xy-
litol is of plant origin, it may compete with glucose or another mono-
saccharide that is used for several glycosylation reactions of proteins in
the ER. Our prior relevant data showed that the glycosylation state is
altered by xylitol treatment (data not shown), and this may be followed
by a marked increase in misfolded proteins that are linked to ER stress.
This idea may be supported by the finding that a major ER-stress in-
ducer, tunicamycin, mediated the incomplete glycosylation of proteins
that can readily induce protein misfolding [21].
4.3. Xylitol exerts selective apoptotic cell death in cancer cells
Another question is why cancer selectivity exists for the xylitol-
mediated ER stress. This may be explained by an increase of xylitol
uptake in cancer cells in comparison to that in normal cells. This may be
similar to the case of glucose uptake in cancer cells, since mono-
saccharide glucose is highly incorporated into many types of cancer
cells due to the significantly elevated expression of glucose membrane
transporters. The glucose transporters belong to the family of solute
carrier SLC genes. Since xylitol transporter(s) are probably present in
the same gene family, we are now attempting to identify xylitol-specific
transporter(s) that are clearly expressed in cancer cells from among the
SLC family members (423 genes); we have narrowed down the candi-
dates to seven candidates.
However, we should not disregard another possible explanation for
the different reactions to xylitol between normal cells and cancer cells.
This may be explained by the differences in the intracellular behaviors
of xylitol and its metabolites in the cells, since a series of enzymes that
play a part in catalyzing xylitol are inevitably present in different states
of expression and activity in the individual cell types. Molecules that
have resistant functions to ER stress or apoptosis may also contribute.
Taken together, the present and past findings highlight the need for
further comprehensive analyses including membrane transporters, xy-
litol metabolites and intracellular proteins to expand our understanding
of the complex mechanism(s) of xylitol sensitivity and resistance, which
may explain how cells acquire xylitol selectivity or specificity.
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4.4. Xylitol may sensitize cancer stem cells to chemotherapeutic drugs
Our data also show that the anticancer effect of xylitol is moderate
but that xylitol has a definite ability to enhance the effects of common
anticancer drugs such as 5-FU [22] when combined with them. Thus,
the control of glutathione at a low level that induces oxidative stress in
a cancer-selective manner may greatly contribute to the effects of an-
ticancer drugs. In addition, the strategy of maintaining the intracellular
glutathione at a low level provides a great benefit when we target
cancer stem cells, since cell surface membrane protein CD44 variant
isoform (CD44v)-positive cancer stem cells frequently show much
higher levels of glutathione due to the enhanced uptake of materials
(e.g., cysteine and glutamate) that are used to make glutathione, and
thereby cancer stem cells display quite high resistance to the oxidative
stress caused by chemotherapeutic drugs [23].
It was reported that an inhibitor of xCT (another glutathione reg-
ulator that functions as a cysteine and glutamate transporter, whose
activity is upregulated by the interaction with CD44v), i.e., sulfasala-
zine, suppresses CD44v-positive cancer stem cell growth [23]. The
antitumor effect of cisplatin at a low dose (2 mg/kg) was significantly
enhanced by treatment with sulfasalazine. Taken together, these results
indicate that not only sulfasalazine but also xylitol reduces the ROS
defense capacity of cancer cells (including cancer stem cells) and sen-
sitizes them to chemotherapeutic drugs.
4.5. Xylitol may prevent cancer invasion and metastasis
Xylitol may have another ability to prevent important cancer events
such as cancer metastasis. Regarding cancer inflammation, using our
melanoma dissemination model and our subsequent lung metastasis
model, we previously demonstrated that S100A8/A9 (a heterodimer
complex of S100A8 and S100A9) plays a crucial role in melanoma
metastasis [24–33]. This protein has an interesting feature of high se-
cretion in melanomas that surround skin stroma and remote lung sites.
We previously demonstrated that S100A8/A9 at melanomas sur-
rounding stroma in the skin strongly stimulate melanoma invasion,
leading to local dissemination [32]. The melanoma-mediated S100A8/
A9 secretion from the lung also stimulates the disseminated melanoma
in the skin to metastasize to the lung, resulting in lung tropic metastasis.
Herein, to examine this additional therapeutic benefit of xylitol, we
investigated S100A8/A9 induction in xylitol-treated melanoma-bearing
mice, and we observed that xylitol shows a trend of preventing
S100A8/A9 induction in the lung (Supplementary Fig. S6). We also
observed a major difference in the inoculated tumor surfaces between
the xylitol-treated and not-treated mice, i.e., smooth versus rough sur-
faces (Figs. 4F and 5D). The rough surface represents an aggressively
infiltrating phenotype of melanoma, probably caused by surrounding
S100A8/A9, whereas xylitol may suppress S100A8/A9 induction in the
melanoma skin area, eventually leading to the prevention of the local
dissemination.
It has also been reported that xylitol efficiently blocked inflamma-
tion [34]. Because inflammation readily induces S100A8/A9, the
blocking of S100A8/A9 induction by treatment with xylitol may pro-
vide another therapeutic benefit against cancer. In the present study,
we were not able to determine whether xylitol can prevent cancer
metastasis. This is because our mouse model used herein is not suitable
as an evaluation model of cancer metastasis; in addition, the shorter
evaluation schedule was not long enough to induce cancer metastasis
from the developed tumor area. We have only speculation based on the
results of the analysis of S100A8/A9 in the lung combined with our
findings [24–33] and those of others [34] as mentioned above. We are
planning to thoroughly investigate the anti-metastatic effect of xylitol
in an optimal mouse model in the future, based on our current findings
regarding S100A8/A9-mediated cancer metastasis.
5. Conclusion
In conclusion, our results support the notion that xylitol has a
tumor-suppressive function that acts via oxidative stress, which is
caused by the xylitol-triggered ER stress, by which a marked level of
CHAC1 is induced and reduces cellular glutathione. The xylitol-medi-
ated oxidative stress greatly contributes to an enhancement of the an-
ticancer effect of the chemotherapeutic drug 5-FU in vitro as well as in
vivo. Taken together, our past and present findings indicate that the use
of xylitol as an adjunct to chemotherapy may be an effective approach
for improving therapeutic outcomes, similarly to sulfasalazine.
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